Interestingly, AR agonist treatment in breast cancer models reprograms binding of both FOXA1 and ESR (Ponnusamy et al., 2019), suggesting some degree of antagonistic function between the androgen and estrogen receptors. This evidence concerns the gene AR and breast carcinoma.